We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+20.46%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$261M
AUM Growth
+$113M
Cap. Flow
+$81.2M
Cap. Flow %
31.18%
Top 10 Hldgs %
68.46%
Holding
45
New
14
Increased
8
Reduced
6
Closed
12

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$24.2M
2
CELG
Celgene Corp
CELG
+$17.8M
3
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$15.1M
4
FOLD
Amicus Therapeutics
FOLD
+$12.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.53M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$5.7M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.5M
3
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$4.62M
4
ARWR icon
Arrowhead Research
ARWR
+$3.88M
5
DVAX
Dynavax Technologies
DVAX
+$3.36M

Sector Composition

Rank Sector Weight
1 Healthcare 83.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$45.8M 17.58%
4,211,399
+1,387,214
+49% +$12.2M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$2.04B
$26M 9.99%
+2,149,907
New +$24.2M
SRNE
3
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$25.6M 9.82%
2,214,043
+1,303,943
+143% +$15.1M
CELG
4
DELISTED
Celgene Corp
CELG
$17.2M 6.58%
+148,800
New +$17.8M
PTX
5
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$14.9M 5.72%
139,517
+26,059
+23% +$2.48M
BLCM
6
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$11M 4.22%
47,502
+25,502
+116% +$6.17M
AGEN
7
Agenus
AGEN
$276M
$10.5M 4.03%
104,344
-30,066
-22% -$3M
EBS icon
8
Emergent Biosolutions
EBS
$379M
$9.51M 3.65%
330,635
– –
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.41M 3.61%
+320,867
New +$7.53M
LJPC
10
DELISTED
La Jolla Pharmaceutical Company
LJPC
$8.45M 3.24%
461,499
+215,000
+87% +$4.36M
TARO
11
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$7.59M 2.91%
53,800
-30,000
-36% -$4.62M
CASC
12
DELISTED
Cascadian Therapeutics, Inc.
CASC
$7.32M 2.81%
748,606
+250,000
+50% +$2.45M
RCPT
13
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$7.25M 2.78%
44,000
-43,500
-50% -$5.5M
STML
14
DELISTED
Stemline Therapeutics, Inc.
STML
$6.87M 2.64%
+475,000
New +$7.27M
TLGT
15
DELISTED
Teligent, Inc
TLGT
$5.88M 2.26%
72,091
+25,857
+56% +$2.5M
QURE icon
16
uniQure
QURE
$2.78B
$5.51M 2.11%
+226,456
New +$4.94M
TNXP icon
17
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
VCEL icon
18
Vericel Corp
VCEL
$2.38B
$3.92M 1.5%
1,058,820
– –
AVDL
19
DELISTED
Avadel Pharmaceuticals
AVDL
$3.88M 1.49%
215,705
+900
+0.4% +$14.1K
SGMO
20
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.83M 1.47%
+244,199
New +$3.78M
TRIL
21
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.23M 1.24%
+160,697
New +$2.37M
CCXI
22
DELISTED
ChemoCentryx, Inc.
CCXI
$2.44M 0.94%
+323,607
New +$2.53M
TXMD icon
23
TherapeuticsMD
TXMD
$23.8M
$2.37M 0.91%
+7,840
New +$1.91M
FBIO icon
24
Fortress Biotech
FBIO
$111M
$2.31M 0.89%
+40,000
New +$1.67M
CRDF icon
25
Cardiff Oncology
CRDF
$63M
$2.21M 0.85%
+4,496
New +$1.92M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Avoro Capital Advisors held 45 positions worth $261M, up 77% from $148M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Avoro Capital Advisors deployed $81.2M of net new capital in Q1 2015, opening 14 new positions and adding to 8 existing holdings. Its largest new stake was Iovance Biotherapeutics: 2,149,907 shares worth $26M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $5.5M trimmed.

  • Avoro Capital Advisors's largest Q1 2015 buy was Iovance Biotherapeutics: 2,149,907 shares worth $26M.
  • Avoro Capital Advisors added most to Sorrento Therapeutics, Inc. in Q1 2015, an estimated $15.1M increase.
  • Avoro Capital Advisors's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $5.5M.
  • Avoro Capital Advisors fully exited MacroGenics in Q1 2015, selling an estimated $5.7M.
  • Avoro Capital Advisors's ten largest holdings make up 68% of its $261M portfolio in Q1 2015.
  • Avoro Capital Advisors opened 14 new positions and closed 12 in Q1 2015.
  • Avoro Capital Advisors's portfolio value rose 77% quarter-over-quarter to $261M.

Based on Avoro Capital Advisors's 13F filing for Q1 2015, filed 15 May 2015.